Working… Menu

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02562118
Recruitment Status : Recruiting
First Posted : September 29, 2015
Last Update Posted : October 5, 2020
Eisai Co., Ltd.
Information provided by (Responsible Party):
National University Hospital, Singapore